Amicrobe Inc. dba Macro Biologics has filed a notice of an exempt offering of securities to raise $5 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Amicrobe Inc. dba Macro Biologics is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Michael Bevilacqua played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Amicrobe Inc. dba Macro Biologics
Macro Biologics creates synthetic macro biologics for breakthrough therapeutics, next generation medical devices, and biomaterials safe for the environment. Our first class, called Amicidins, combines beneficial physical properties with broad microbicidal activity. They are the foundation of four investigational products targeting the life-threatening infections of surgery and trauma.
To learn more about Amicrobe Inc. dba Macro Biologics, visit http://www.macrobiologics.com/
Contact:
Michael Bevilacqua, President and Chief Executive Officer
888-490-1180
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.